Matthews Pacific Tiger Active ETF (ASIA)
Live price chart, market sentiment, and community perspectives for Matthews Pacific Tiger Active ETF (AMEX: ASIA).
Live price chart, market sentiment, and community perspectives for Matthews Pacific Tiger Active ETF (AMEX: ASIA).
On our macro desk, we are closely tracking the valuation dynamics of the Matthews Pacific Tiger Active ETF (ASIA) as it trades around $41.40. With a modest market capitalization of $51.75M, the fund's asset allocation profile—consisting of 89.71% non-US stocks and 10.29% cash—offers a concentrated play on the Pacific/Asia ex-Japan space. However, sentiment is tempered by recent performance data showing a -0.2% return in June 2026, earning it a mediocre C grade in its category.
Looking at the structural risks for ASIA, our risk management group flagged heavily elevated risks stemming from poor secondary market liquidity. While Kathy Xu stepped in as a Portfolio Manager in 2026 to steer day-to-day operations under the fund's 80% non-US investment mandate, the small asset base requires cautious execution sizing to avoid slippage during volatile regional sessions.
When analyzing active non-US ETF mandates like ASIA, candidate interviews should focus heavily on understanding how portfolio managers navigate regional market friction and cash drag. With 10.29% currently parked in cash and the remainder in non-US equities, the fund's strategy relies heavily on active stock selection to overcome category headwinds, especially given its recent C-grade performance ranking.
Our quantitative screen highlights the absolute lack of US stock and bond exposure in ASIA, as the portfolio sits firmly at roughly 89.71% non-US equities and 10.29% cash. This pure-play regional posture means currency fluctuations and regional market sentiment dictate nearly the entirety of the fund's daily PandL, amplifying the importance of tracking secondary market trading spreads.
From a hedge fund perspective, the micro-cap nature of ASIA at $51.75M makes it an interesting vehicle for targeted regional exposure, but the trailing returns and category positioning warrant close monitoring. The shift in leadership under Kathy Xu in 2026 introduces a new variable for institutional allocators evaluating the fund's ability to alpha-generate against passive benchmarks in the Pacific/Asia ex-Japan space.
Explore plasma cleansing, somatic organ swaps, and BCI.